Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Bausch Health Companies Inc.

BHC ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: HOLD

Last Close

$6.04

▲ +0.00%

Market Cap $2.27B · Vol 275.33K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: 1.36

Market Cap

$2.27B

Mid Cap

Div Yield

N/A

EPS Growth

+22.65%

YoY

RSI (14)

67.54

Momentum

Beta

0.38

vs Market

52W High

$8.00

24.50% below

52W Low

$4.34

39.33% above

Volume

275.33K

Avg 489.41K

P/B

N/A

Price-to-book

ROE

-152.75%

Return on equity

Free Float

87.31%

Public shares

Shariah Compliance8 STANDARDS

✗ Bausch Health Companies Inc. (BHC) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BHC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.14%

-1.95%

+24.28%

+12.06%

YTD

-13.09%

-5.48%

-22.37%

-78.31%

Financials & Valuation

TTM · Annual

Total Revenue	$10.27B
Net Income	$120.00M
Revenue Growth (YoY)	+12.73%
Gross Margin	60.90%
Operating Margin	21.28%
Net Profit Margin	1.17%
ROE	-152.75%
ROA · ROIC	1.39% · 3.22%

P/E Ratio	N/A
Forward P/E (FY1)	1.36
PEG Ratio	0.04
P/S	0.25
P/B	N/A
P/FCF	2.62
EPS Growth	+22.65%
Outstanding Shares	374.14M

Technical Indicators

50-Day SMA	$6.21
200-Day SMA	$5.76
RSI (14)	67.54
Beta	0.38
52-Week High	$8.00
52-Week Low	$4.34

Volume Today	275.33K
Avg Daily Volume (30D)	489.41K
Relative Volume	0.56x
Volatility (10D)	21.42
Volatility (30D)	33.54
Free Float	87.31%

Analyst Consensus

HOLD

Current Price $6.04

Mean Target $7.50

52W Low$4.34 52W High$8.00

Current

Target

$4.34 $8.00

Current Analyst target

+24.17% upside potential · 5 analysts

Identifiers

ExchangeNYSE

FIGIBBG001S7WDP0

ISINCA0717341071

CountryCanada

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +0.83% JNJ Johnson & Johnson +1.93% ABBV AbbVie Inc. +1.49% NVS Novartis AG +0.45% NOVN.S Novartis AG +1.17%

Company Profile

Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.